vTv Therapeutics Inc. Class A Common Stock, also called vTv Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Read More Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.